
News|Articles|April 1, 2011
FDA Pipeline Preview, April 2011 (Salix, Protalix, Amyvid, indacaterol, Istodax, Mucin 1 targeting peptide GO-203-2c, Intercept plasma, Lomitapide, Liver cell therapy)
Recent FDA action (through, March 2011) related to Salix, Protalix, Amyvid, indacaterol, Istodax, Mucin 1 targeting peptide GO-203-2c, Intercept plasma, Lomitapide, Liver cell therapy.
Advertisement
Complete response
Recommendations for approval
Priority review
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
7 things you need to know about the PBM reforms signed into law this week
2
PBM reform. It has finally happened
3
TrumpRx launches; some experts question its long-term value
4
FDA issues draft guidance on MRD and complete response as primary endpoints for accelerated multiple myeloma drug approvals
5

























